bioRxivMicrobiology
Targeting CTP Synthetase 1 to Restore Interferon Induction and Impede Nucleotide Synthesis in SARS-CoV-2 Infection
Y. Rao, T.-Y. Wang, C. Qin, B. Espinosa, Q. Liu, A. Ekanayake, J. Zhao, A. C. Savas, S. Zhang, M. Zarinfar, Y. Liu, W. Zhu, N. A. Graham, T. Jiang, C. Zhang, P. Feng
Abstract
The newly emerged SARS-CoV-2 caused a global pandemic with astonishing mortality and morbidity. The mechanisms underpinning its highly infectious nature remain poorly understood. We report here that SARS-CoV-2 exploits cellular CTP synthetase 1 (CTPS1) to promote CTP synthesis and suppress interferon (IFN) induction. Screening a SARS-CoV-2 expression library identified ORF7b and ORF8 that suppressed IFN induction via inducing the deamidation of interferon regulatory factor 3 (IRF3). Deamidated IRF3 fails to bind the promoters of classic IRF3-responsible genes, thus muting IFN induction. Conversely, a shRNA-mediated screen focused on cellular glutamine amidotransferases corroborated that CTPS1 deamidates IRF3 to inhibit IFN induction. Functionally, ORF7b and ORF8 activate CTPS1 to promote de novo CTP synthesis while shutting down IFN induction. De novo synthesis of small-molecule inhibitors of CTPS1 enabled CTP depletion and IFN induction in SARS-CoV-2 infection, thus impeding SARS-CoV-2 replication. Our work uncovers a strategy that a viral pathogen couples immune evasion to metabolic activation to fuel viral replication. Inhibition of the cellular CTPS1 offers an attractive means for developing antiviral therapy that would be resistant to SARS-CoV-2 mutation.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Synergistic interference with SARS-CoV-2 replication by Molnupiravir-derived N4 hydroxycytidine and inhibitors of CTP synthetase
Kim M. Stegmann, Antje Dickmanns, … Matthias Dobbelstein·bioRxiv·Mar 6, 2025
- A path towards SARS-CoV-2 attenuation: metabolic pressure on CTP synthesis rules the virus evolution
Zhihua Ou, Christos A. Ouzounis, … Antoine Danchin·Genome Biology and EvolutionPeer-reviewed·Oct 28, 2020
- SARS-CoV-2 S protein antagonizes type I interferon downstream signal pathway through interacting and attenuating phosphorylation of STAT1/STAT2
- The Zinc Finger Antiviral Protein restricts SARS-CoV-2
R. Nchioua, D. Kmiec, … F. Kirchhoff·bioRxiv·Jun 4, 2020
- Parsing the role of NSP1 in SARS-CoV-2 infection
T. Fisher, A. Gluck, … N. Stern-Ginossar·bioRxiv·Mar 14, 2022
- SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways
L. Han, M.-W. Zhuang, … C. Gao·bioRxiv·Aug 16, 2020